Recursion Pharmaceuticals

Recursion Pharmaceuticals Recursion is a clinical stage TechBio company decoding biology to industrialize drug discovery and radically improve lives.

Traditional drug discovery methods are inefficient and expensive – approximately 90% of all drugs in clinical trials ultimately fail to get approved and the total investment needed to develop each approved medicine exceeds $2 billion. This inefficiency occurs because biology is extraordinarily complex, and our industry has historically lacked the tools to understand how it functions. At Recursion,

we’re harnessing the convergence of multiple breakthrough technologies that allow our scientists to explore uncharted areas of biology and unravel its complexity to navigate the path to better treatments. We have built a massive proprietary biological and chemical database that predicts trillions of relationships across biology and chemistry, many of which are not known in scientific literature. Our approach generates novel insights, broadens the scope of potential medicines, and truly industrializes drug discovery – increasing the scale, speed and efficiency of each step of the process. We believe our technology and approach has the potential to not only radically improve the lives of patients, but also change the landscape of drug discovery and development forever.

🎉 We won! Proud to announce that Recursion has won a Fierce AI Innovation Award for AI Innovation in Drug Discovery. 🔹Th...
09/02/2026

🎉 We won!

Proud to announce that Recursion has won a Fierce AI Innovation Award for AI Innovation in Drug Discovery.

🔹The award recognizes the impact of the Recursion OS which connects biology, design, and clinical development into a single AI product engine.

They note that this engine is more than a collection of point solutions. “Instead of stitching together fragmented public datasets, Recursion generates its own proprietary data at industrial scale and feeds it directly back into the system.”

👉Read more: https://www.fiercepharma.com/ai-and-machine-learning/drug-discovery

Recursion CEO Najat Khan, PhD is speaking at the World Medical Innovation Forum in Boston on Sept. 23 as part of the pan...
09/01/2026

Recursion CEO Najat Khan, PhD is speaking at the World Medical Innovation Forum in Boston on Sept. 23 as part of the panel “Riding the AI Tsunami: How Organizations Are Driving Cultural Change.”

The Forum is presented by Mass General Brigham and Bank of America, and brings together global leaders across healthcare, life sciences, and investment to assess what’s advancing and what it takes to move innovation at speed and scale.

👉 Learn more and register here: https://2026.worldmedicalinnovation.org/

08/12/2026

Working on difficult-to-drug targets can feel like walking a tight rope through chemical space.

At Recursion, we’re using AI agents to work alongside our scientists, and help us navigate that tight rope with precise steps.

🚀 How we unlocked the first neuroscience target for the Recursion and Genentech collaboration.The collaboration began wi...
08/06/2026

🚀 How we unlocked the first neuroscience target for the Recursion and Genentech collaboration.

The collaboration began with a mission to unlock new targets in one of medicine’s most challenging therapeutic areas: neuroscience. Today, that work has reached an important milestone, with the first previously unexplored neuroscience target advancing into a joint early discovery program.

In a new story from Fabienne Kinzelman in Bloomberg Business – and our latest blog – we share how the team developed new manufacturing processes to produce more than 1 trillion hiPSC-derived neuronal cells, systematically perturbed 17,000+ genes, captured 30 million+ cellular images, and built a foundation model to create an AI-enabled Map of Biology capable of surfacing unexplored biology in neuroscience.

Read the Bloomberg story with this gift link: https://www.bloomberg.com/news/articles/2026-08-05/roche-advances-ai-derived-drug-target-with-partner-recursion?accessToken=eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJzb3VyY2UiOiJTdWJzY3JpYmVyR2lmdGVkQXJ0aWNsZSIsImlhdCI6MTc4NTkzMTE4NSwiZXhwIjoxNzg2NTM1OTg1LCJhcnRpY2xlSWQiOiJUSjhKN0NUOU5KTFMwMCIsImJjb25uZWN0SWQiOiJENUU4MTcxNEU1MDI0QUI1OEIwRjE5OEI3OUUzRUM5QyJ9.9ss51QWPO8R2-Evf6NYOUaGDR7qIPNpDjrECLqG6IqI
Check out the blog: https://recursion.com/news/unlocking-the-first-neuroscience-target-for-the-recursion-and-genentech-collaboration

🚀 How we unlocked the first neuroscience target for the Recursion and Genentech collaboration.The collaboration began wi...
08/06/2026

🚀 How we unlocked the first neuroscience target for the Recursion and Genentech collaboration.

The collaboration began with a mission to unlock new targets in one of medicine’s most challenging therapeutic areas: neuroscience. Today, that work has reached an important milestone, with the first previously unexplored neuroscience target advancing into a joint early discovery program.

In a new story from Fabienne Kinzelmann in Bloomberg Business – and our latest blog – we share how the team developed new manufacturing processes to produce more than 1 trillion hiPSC-derived neuronal cells, systematically perturbed 17,000+ genes, captured 30 million+ cellular images, and built a foundation model to create an AI-enabled Map of Biology capable of surfacing unexplored biology in neuroscience.

Read the Bloomberg story with this gift link: https://www.bloomberg.com/news/articles/2026-08-05/roche-advances-ai-derived-drug-target-with-partner-recursion?accessToken=eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJzb3VyY2UiOiJTdWJzY3JpYmVyR2lmdGVkQXJ0aWNsZSIsImlhdCI6MTc4NTkzMTE4NSwiZXhwIjoxNzg2NTM1OTg1LCJhcnRpY2xlSWQiOiJUSjhKN0NUOU5KTFMwMCIsImJjb25uZWN0SWQiOiJENUU4MTcxNEU1MDI0QUI1OEIwRjE5OEI3OUUzRUM5QyJ9.9ss51QWPO8R2-Evf6NYOUaGDR7qIPNpDjrECLqG6IqI
Check out the blog: https://recursion.com/news/unlocking-the-first-neuroscience-target-for-the-recursion-and-genentech-collaboration

Today, Recursion reports its second quarter financial results and business updates, showing demonstrated progress across...
08/05/2026

Today, Recursion reports its second quarter financial results and business updates, showing demonstrated progress across partnerships, clinical programs and financial goals.

“Recursion has reached a pivotal point where our AI-native engine is translating unique data into potential first-in-class therapeutic opportunities,” said Recursion CEO Najat Khan, PhD. “The advancement of the first unexplored neuroscience target from our collaboration with Roche and Genentech into an early discovery program is an important proof point. Finding new targets in neuroscience has historically been challenging, and this milestone highlights our ability to uncover novel biology in areas where conventional approaches have struggled.”



More: https://share.google/tKCh6w15lI4ixJtrh

07/31/2026

Living with FAP.

Familial adenomatous polyposis (FAP) is a challenging rare disease with no current treatments. Patients like Jenny Jones will develop hundreds to thousands of polyps and require regular surveillance and life-altering surgeries. Without these surgeries, they face a near 100% cancer risk.

Recursion is currently evaluating an investigational medication, REC-4881, developed using its AI platform. The TUPELO clinical research study is now enrolling eligible patients 18 and older with FAP at sites across the country.

Learn more: Familial Adenomatous Polyposis (FAP) Clinical Trial | Tupelo Study: https://recursion.com/clinical-trials/familial-adenomatous-polyposis-clinical-trial

Recursion will host its second quarter financial results and business updates in an Earnings Call on August 5, 2026 at 8...
07/29/2026

Recursion will host its second quarter financial results and business updates in an Earnings Call on August 5, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm BST.

🔹Join the call on:
▪️LinkedIn: https://www.linkedin.com/company/recursion-pharmaceuticals
▪️YouTube: https://www.youtube.com/
▪️X: https://x.com/RecursionPharma

Analysts, investors, and the public have the opportunity to ask questions by submitting questions here: https://forms.gle/tcYtfHRL8KagYZQw9

👉More: https://ir.recursion.com/news-releases/news-release-details/recursion-report-second-quarter-2026-business-updates-and

07/20/2026

🚀 A better, faster co-folding-based binding affinity model.

Predicting how tightly a drug candidate binds to its target is critical in drug discovery. It also requires massive computational resources. State-of-the-art models can take 20 seconds to a minute per prediction, impractical for the demands of large scale early-stage programs .

💠 Today, Recursion’s Valence Labs is releasing Nesso-1: the fastest open-source co-folding-based binding affinity model available.

At 1 second per prediction, it’s roughly 20x faster than our previous collaboration on Boltz-2 while matching or surpassing its accuracy across public and internal benchmarks. By leveraging NVIDIA cuEquivariance, we’ve been able to further accelerate both training and inference by an additional 2-3x. We look forward to continuing to improve Nesso-1 in collaboration with NVIDIA. Weights and code are fully open-sourced.

The core architectural ideas behind Nesso-1 build on the insight that coarse-grained co-folding representations can match full-atom models for affinity prediction at a fraction of the cost. Nesso is the first open implementation of this approach with no proprietary dependencies, trained entirely on public data, built to be reproducible and extensible.

We’re already using Nesso-1 internally in active drug discovery programs. Fast, reliable affinity prediction at scale is foundational to the kind of autonomous design loops that define our vision for Autonomous Precision Design and Nesso is a meaningful step toward that.

👉 Report:https://www.valencelabs.com/wp-content/uploads/2026/07/nesso1.pdf
👉 Github: https://github.com/recursionpharma/nesso
👉 HF: https://huggingface.co/recursionpharma/nesso

Address

41 S Rio Grande Street
Salt Lake City, UT
84108

Alerts

Be the first to know and let us send you an email when Recursion Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Recursion Pharmaceuticals:

Shortcuts

Share